Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beroctocog alfa - GC Pharma

Drug Profile

Beroctocog alfa - GC Pharma

Alternative Names: GC 1101; GC 1101C; GC1101 D; GreenGene F; r-FVIII - GC Pharma; Recombinant factor VIII - GC Pharma

Latest Information Update: 01 Mar 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Green Cross
  • Developer GC Pharma
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Haemophilia A

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 22 Aug 2017 Beroctocog alfa is available for licensing as of 22 Aug 2017. http://www.greencross.com/eng/business/licensigout.do
  • 22 Aug 2017 Phase-III clinical trials in Haemophilia A in China (IV) before August 2017 (Green Cross pipeline, August 2017)
  • 01 Apr 2013 Phase-III clinical trials in Haemophilia A (In adolescents, In adults, In the elderly) in Canada, New Zealand, Poland, Russia and Ukraine (IV) after January 2013 (NCT01619046)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top